Normal view
- The Debrief
- 5,000-Year-Old Blue Pigment Reveals Evidence of Ancient Egyptian Nanotechnology—Now It’s Finding New Life in Biomedical Imaging
5,000-Year-Old Blue Pigment Reveals Evidence of Ancient Egyptian Nanotechnology—Now It’s Finding New Life in Biomedical Imaging
Thousands of years ago, a striking blue pigment began appearing in the art that adorned the walls of ancient Egyptian tombs, and eventually on the crown of the famous bust of Nefertiti, wife of the 18th dynasty pharaoh Akhenaten and half-sister to one of Ancient Egypt’s most famous kings: Tutankhamun.
However, the ancient artists who first used this remarkable pigment, known today as “Egyptian blue,” had likely never guessed that thousands of years into the future, this unique substance would have applications in modern biomedical research.
That is precisely what one team of researchers discovered several years ago, in a study that revealed how this striking pigment is more than just a modern medical marvel with origins in the ancient world—it also provides evidence of ancient nanotechnology in early Egypt.
The Enigma of Egyptian Blue
“Egyptian blue” is the common term for a pigment first developed in ancient Egypt around 2500 B.C., made from calcium copper silicate. Originally, it was created to provide an artificial alternative to a more costly form of blue pigment from the era, which was produced using lapis lazuli.
However, ancient Egyptian scientists discovered that by heating limestone, sand, and copper, they could produce a far less expensive form of blue pigment, and soon its use spread throughout the ancient Mediterranean world, making its way into the craftsmanship in parts of the ancient world that ranged from Mesopotamia to Greece and Rome.
An Ancient Technology Finds Modern Biomedical Applications
Although Egyptian blue’s obvious practical uses in art were derived from its unique and stunning appearance, time would eventually reveal that it had other uses. Specifically, in a 2020 study published in Nature Communications, a team of researchers reported on their discovery that Egyptian blue in its powdered form can be separated into nanoscale sheets roughly 100,000 times thinner than a human hair.
This is significant because these tiny particles of the substance exhibit significant fluorescence under near-infrared light, which can be used by researchers to track them within biological samples.
Chemist Sebastian Kruss of Georg-August University Göttingen, the lead author of the 2020 study, remarked at the time that he was certain such capabilities “will be of growing interest for material scientists as well as biomedical research” in the years ahead.
Ancient Nanotech’s Survival Through the Centuries
One reason the pigment is so useful is also the likely reason behind its discovery, and that is Egyptian blue’s durability. For many millennia, samples of this unique material have managed to survive, and the material’s nanoscale form remains stable even over such long periods.
In the past, earlier studies had demonstrated that the material fluoresces in near-infrared wavelengths. Additionally, it was known to scientists that the pigment could be broken down into flakes after being stirred in hot water for periods of several days.
Building on this knowledge, the research detailed in the 2020 paper sought to go even further by examining whether those particles could function as fluorescent markers in living systems.
Near-Infrared Applications
One thing that scientists find useful about near-infrared imaging is that it provides an effective way to examine biological material by leveraging wavelengths that fall just beyond the ranges of the visible spectrum.
Although some molecules can already be used as fluorescent markers, Egyptian blue nanoparticles generate significantly brighter signals than several common alternatives. Additionally, unlike other fluorescent compounds, the pigment can resist photobleaching, which is important because this allows its glow to persist even during prolonged observation.
A pair of experiments was used by the team to demonstrate the material’s potential. The first involved using Egyptian blue particles injected within a fruit fly embryo, which were tracked as it developed. In another, the particles were added to plant leaves, allowing comparisons with the performance of a conventional near-infrared imaging molecule.
In this experiment, the team found that the Egyptian blue produced a bright signal that remained visible even against the leaves’ natural fluorescence—the comparison molecule, by contrast, was heavily obscured.
According to Kruss, the tiny Egyptian Blue particles prove to be “very useful glowing labels in biomedical research,” calling the pigment a “very powerful fluorophore.”
An Ancient Discovery Breaking New Ground in the 21st Century
According to Kruss and his colleagues, such particles could eventually help scientists observe processes including embryonic development and cell division, while potentially supporting applications such as image-guided surgery and the labeling of cancerous tissue.
Altogether, this enigmatic form of ancient nanotechnology is still playing a role in helping develop the cutting-edge biomedical technologies of tomorrow, even more than 5,000 years after its initial discovery.
Kruss and his team’s original paper from 2020, “Exfoliated near infrared fluorescent silicate nanosheets for (bio)photonics,” was published in Nature.
Micah Hanks is the Editor-in-Chief and Co-Founder of The Debrief. A longtime reporter on science, defense, and technology with a focus on space and astronomy, he can be reached at micah@thedebrief.org. Follow him on X @MicahHanks, and at micahhanks.com.
Second PSMA PET Scan Finds Hidden Prostate Cancer in 56% of Patients
Retinal Imaging Reveals Key Predictors of Alzheimer’s Disease Risk
Often hailed as “the window to the soul,” the human eye has long fascinated scientists and philosophers alike. However, beyond its poetic allure, emerging research suggests that the eyes provide a vital window into the health of the brain. A groundbreaking new study spearheaded by the University of Florida’s biomedical engineering department has unveiled a transformative approach to predicting Alzheimer’s disease risk factors by analyzing retinal photographs with cutting-edge deep learning algorithms. This development promises to revolutionize early detection and intervention for one of the most devastating neurodegenerative diseases.
Traditionally, diagnosing Alzheimer’s disease has been a challenge due to its insidious onset and prolonged development over decades. Most diagnostic protocols focus on detecting the disease in its later stages, by which time significant, irreversible brain damage has already occurred. Recognizing this limitation, Dr. Ruogu Fang and her interdisciplinary team leveraged advances in artificial intelligence and biomedicine to explore the retina—a part of the central nervous system accessible via non-invasive imaging—as a potential biosensor for Alzheimer’s risk.
The study capitalized on a rich database of over 40,000 retinal images collected from the UK Biobank, a comprehensive health resource with longitudinal patient data. Retinal photography is commonly conducted during routine eye exams, diabetes management, glaucoma monitoring, and cataract assessments. By harnessing these widely available, inexpensive images, the research team circumvented the need for costly, invasive, or logistically complex diagnostic tools such as MRI or PET scans, thus holding promise for scalable, population-wide screening.
Employing deep learning, a subset of machine learning characterized by neural networks modeled after the human brain, the researchers developed an AI framework that scrutinized retinal morphology. This model was able to discern subtle variations in retinal arteries, veins, and the optic nerve head, features imperceptible to the human eye but correlated strongly with known risk factors for Alzheimer’s disease. Such morphological markers serve as proxies for neurovascular health, which is crucial given Alzheimer’s recognized association with vascular impairment.
One of the most striking revelations of this research was the model’s capacity not only to predict intrinsic biological traits such as sex and blood pressure but also modifiable lifestyle factors that influence Alzheimer’s risk. The AI effectively inferred behaviors like smoking, alcohol consumption, and even insomnia from retinal images alone. This objective measurement circumvents the notorious unreliability of self-reported lifestyle data, often plagued by bias and inaccuracies, thereby enriching risk assessment precision.
As Dr. Fang points out, retinal morphology functions less like a mere clinical questionnaire and more like an integrative biological sensor reflecting a cumulative lifetime burden of neurovascular and lifestyle insults. This conceptual shift underscores the retina’s role in encapsulating decades of physiological data, transforming retinal imaging into a powerful tool for capturing both present health and future vulnerability.
Furthermore, the implications extend beyond risk prediction. Identifying individuals with early signs of retinal changes could trigger timely clinical interventions long before cognitive symptoms manifest. Such preclinical detection enables the implementation of protective lifestyle adjustments, pharmacological therapies, or cognitive training programs designed to delay or mitigate Alzheimer’s progression.
The pioneering work built on previous findings from Fang’s group that demonstrated retinal images’ utility in detecting active Alzheimer’s disease cases. However, this new model pioneers the field by focusing on prodromal markers and risk factors instead of established dementia, bridging a critical gap in neurodegenerative diagnostics.
Importantly, the use of retinal photographs democratizes neurovascular health monitoring. Since retinal imaging is non-invasive, accessible, and affordable, it offers the prospect of integrating brain health assessment into routine eye care, thus expanding preventive neurology beyond specialized clinical settings.
This research also exemplifies the synergy between computational science and biomedical engineering. By combining sophisticated image analysis algorithms with large-scale patient data, it transcends traditional diagnostic constraints, marrying technology with medicine in a profoundly impactful manner.
While challenges remain, including the need for further validation across diverse populations and integration with other biomarkers, this study sets a new paradigm for early Alzheimer’s disease risk stratification. The possibility of preemptive interventions guided by retinal AI analysis heralds a future where the devastating trajectory of Alzheimer’s may be altered through timely and personalized healthcare.
In summary, the novel application of deep learning to retinal photographs opens an unprecedented window into brain health, heralding a new era of precision neurodiagnostics. It moves us closer to the long-sought goal of identifying Alzheimer’s risk decades in advance, fostering opportunities for early intervention and ultimately, better patient outcomes.
Subject of Research: People
Article Title: Prediction of Alzheimer’s disease risk factors from retinal images via deep learning: Development and validation of biologically relevant morphological associations in the UK Biobank
News Publication Date: 16-Jun-2026
Web References:
DOI: 10.1177/13872877261457650
Keywords
Alzheimer’s disease, Neurodegenerative diseases, Neurological disorders, Eye, Retina, Artificial intelligence, Image analysis, Deep learning, Biomedical engineering, Neurovascular integrity, Retinal biomarkers, Predictive modeling